Skip to content

Nasopharynx Microbiota Component and in Vitro Cytokines Production in Coronavirus Disease (COVID-19)

TUSEB-Nasopharynx Microbiota Component and in Vitro Cytokines Production in Coronavirus Disease (COVID-19)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04708912
Acronym
8796
Enrollment
100
Registered
2021-01-14
Start date
2020-12-15
Completion date
2021-04-01
Last updated
2021-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

The investigators will study nasopharunx microbiota composition, RNA sequences and in vitro cytokines production by peripheral blood cells of COVID-19 patients (both mild-moderate and severe cases) (comparing with convalescent patients and healthy controls).

Detailed description

The investigators will compare study parameters (basal) between mild-moderate and severe COVID-19 patients and with other study groups (i.e. convalescent and healthy controls). Nasopharunx microbiota dysbiosis, in vitro cytokines production profile, and peripheral blood flocytometric results of the four study groups will be compared. In vitro cytokines production will be studied and compared in Nill (No antigens) and Mitojen (Cocktail of antigens) pre-prepared test tubes.

Interventions

OTHERObservation

The study parameters will be obtained at the time of recuirement (Basal)

Sponsors

Başakşehir Çam & Sakura City Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Ability to give a written consent

Exclusion criteria

* In ability to give a written consent * Using of medications that affect the results of study parameters * Presence of malignancy or tuberculosis

Design outcomes

Primary

MeasureTime frameDescription
Determination of peripheral blood RNA microarray assayFirst dayFour study groups, microarray Analysis .
Determination of nasopharunx Microbiota analysis1st dayFour study groups, metagenomic analysis, to determine abundance and decrease of some species.
Determination of in vitro cytokines productionFirst dayIL-2, IL-7, IL-10, granulocyte-colony stimulating factor, interferon-p inducible protein 10, monocyte chemo-attracting protein 1, macrophage inflammatory protein 1-α and tumor necrosis factor-α in Nill (no angijen) and Mitojen (Cocktails of antigens)tubes (between 4 study groups)
Determination of peripheral blood cytometryFirst dayFour study groups, peripheral blood cytometry; CD3, CD4, CD8, and CD45 rates.
Relation between study parametersFirst day parametersdetermining the realtion between microbiotme dysbiosis, in vitro cytokines production and peripheral leymphocytes (CD3,CD4, CD8, and CD45) rates and the severity of COVID-19( if any)

Countries

Turkey (Türkiye)

Contacts

Primary ContactMehmet Hursitoglu, MD
mehmet.hursitoglu@sbu.edu.tr+902129096000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026